Precision BioSciences Appoints Juli Blanche as Chief People Officer
New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience DURHAM, N.C. --(BUSINESS WIRE)--May 23, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical…
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
- ARCUS Genome Editing Achieved Substantial Reductions in both cccDNA and Hepatitis B Surface Antigen (HBsAg), 85% and 77% respectively, in HBV-infected Primary Human Hepatocytes (PHH) - Significant…
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
Multiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout New Primary Hyperoxaluria Type 1…
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years -…
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022--…
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage…
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the…
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene…